Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Cancer Epidemiology and Prevention
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1420518

Chemotherapy Induced Peripheral Neuropathy and its determinants among Adult Cancer Patients on Chemotherapy in Northwest Ethiopia Oncology Centers, 2022

Provisionally accepted
Tesfaye Engdaw Habtie Tesfaye Engdaw Habtie 1*Melsew Dagne Abate Melsew Dagne Abate 2Gebremeskel Kibret Abebe Gebremeskel Kibret Abebe 3Zenaw Tessema Wolie Zenaw Tessema Wolie 4Addis Wondmagegn Alamaw Addis Wondmagegn Alamaw 3Haymanot Zeleke Mitiku Haymanot Zeleke Mitiku 5
  • 1 Department of Nursing, College of Health Science, Woldia University, Woldia, Ethiopia
  • 2 Other, Woldia, Ethiopia
  • 3 Department of Emergency and Critical Care Nursing, School of Nursing, College of Medicine and Health Sciences, Woldia University, Woldia, Ethiopia, Woldia, Ethiopia
  • 4 Department of Pharmacy, College of Health Science, Debre Markos University, Debre Markos, Amhara, Ethiopia
  • 5 College of Health Science, Debre Markos University, Debre Markos, Amhara, Ethiopia

The final, formatted version of the article will be published soon.

    Introduction: Peripheral neuropathy is a nerve problem that causes pain, numbness, and tingling in different parts of the body. It is a major and common clinical problem in a variety of chemotherapeutic medications frequently used for cancer treatments with the frequency of 19 % to 85 %. To the best of the authors' knowledge, there is a lack of data on the magnitude and determinants of chemotherapy induced peripheral neuropathy in Ethiopia. Objective: To assess the magnitude and associated factors of chemotherapy induced peripheral neuropathy among adult cancer patients on chemotherapy in northwest Ethiopia, oncology centers, 2022 Method: An Institutional based cross-sectional study design was conducted on 406 eligible adult cancer patients on chemotherapy in northwest Ethiopia, oncology centers, between, May and July 2022. Results: Out of 406 adult cancer patients included in the study, (54.4%) had peripheral neuropathy. Stage of cancer [AOR=4.36 95% CI: (1.76; 10.8)], Co-morbidity [AOR=2.74, 95% CI: (1.28; 5.83)], Drug regimen [AOR=2.99, 95% CI: (1.36; 6.54)] and Cycle of therapy [AOR=4.00, CI: (1.67; 9.65)] were significantly associated with the magnitude of chemotherapy induced peripheral neuropathy. Conclusion: Chemotherapy induced peripheral neuropathy is a common adverse event in Ethiopian cancer patients managed with different chemotherapeutic drugs. Hence, it is necessary to establish more successful diagnostic methods and incorporate validated scales like European Organization for Research and Treatment of Cancer assessment tools alone or in combination with other clinical tools in the routine evaluation of all patients receiving chemotherapeutic drug.

    Keywords: Cancer, chemotherapy, Ethiopia, peripheral neuropathy, Risk factors

    Received: 16 May 2024; Accepted: 07 Nov 2024.

    Copyright: © 2024 Habtie, Abate, Abebe, Wolie, Alamaw and Mitiku. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Tesfaye Engdaw Habtie, Department of Nursing, College of Health Science, Woldia University, Woldia, Ethiopia

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.